Literature DB >> 19066601

Cancer stem cell-directed therapies: recent data from the laboratory and clinic.

Christopher Y Park1, Diane Tseng, Irving L Weissman.   

Abstract

Cancer stem cells (CSCs) are defined by their ability to (i) fully recapitulate the tumor of origin when transplanted into immunodeficient mouse hosts, and (ii) self-renew, demonstrated by their ability to be serially transplanted. These properties suggest that CSCs are required for tumor maintenance and metastasis; thus, it has been predicted that CSC elimination is required for cure. This prediction has profoundly altered paradigms for cancer research, compelling investigators to prospectively isolate CSCs to characterize the molecular pathways regulating their behavior. Many potential strategies for CSC-directed therapy have been proposed, but few studies have rigorously demonstrated their efficacy using in vivo models. Herein, we highlight recent studies that demonstrate the utility of CSC-directed therapies and discuss the implications of the CSC hypothesis to experimental design and therapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 19066601      PMCID: PMC2835048          DOI: 10.1038/mt.2008.254

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  129 in total

1.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

2.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

Authors:  W Eisterer; X Jiang; O Christ; H Glimm; K H Lee; E Pang; K Lambie; G Shaw; T L Holyoake; A L Petzer; C Auewarakul; M J Barnett; C J Eaves; A C Eaves
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

4.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

5.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Authors:  Benny K Abraham; Peter Fritz; Monika McClellan; Petra Hauptvogel; Maria Athelogou; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

6.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

Review 7.  Cancer stem cells: at the headwaters of tumor development.

Authors:  Ryan J Ward; Peter B Dirks
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

8.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Authors:  Daniel J Pearce; David Taussig; Catherine Simpson; Kirsty Allen; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

Review 10.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  68 in total

Review 1.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

2.  Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study.

Authors:  Scott M Thompson; Matthew R Callstrom; Kim A Butters; Shari L Sutor; Bruce Knudsen; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-23       Impact factor: 2.740

3.  Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.

Authors:  J Geraldo Valadez; Anuraag Sarangi; Christopher J Lundberg; Michael K Cooper
Journal:  J Vis Exp       Date:  2014-01-14       Impact factor: 1.355

4.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

5.  Functional ion channels in stem cells.

Authors:  Gui-Rong Li; Xiu-Ling Deng
Journal:  World J Stem Cells       Date:  2011-03-26       Impact factor: 5.326

6.  The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells.

Authors:  Sang-Soo Kim; Antonina Rait; Farwah Rubab; Abhi K Rao; Michael C Kiritsy; Kathleen F Pirollo; Shangzi Wang; Louis M Weiner; Esther H Chang
Journal:  Mol Ther       Date:  2013-10-11       Impact factor: 11.454

Review 7.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

8.  Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth.

Authors:  Rajneesh Pathania; Sabarish Ramachandran; Gurusamy Mariappan; Priyanka Thakur; Huidong Shi; Jeong-Hyeon Choi; Santhakumar Manicassamy; Ravindra Kolhe; Puttur D Prasad; Suash Sharma; Bal L Lokeshwar; Vadivel Ganapathy; Muthusamy Thangaraju
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

9.  c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.

Authors:  X Xie; T S Kaoud; R Edupuganti; T Zhang; T Kogawa; Y Zhao; G B Chauhan; D N Giannoukos; Y Qi; D Tripathy; J Wang; N S Gray; K N Dalby; C Bartholomeusz; N T Ueno
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

Review 10.  Glioma stem cell research for the development of immunotherapy.

Authors:  Jianfei Ji; Keith L Black; John S Yu
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.